Drug intelligence / Profile preview

SF0013

Development stage: Preclinical
Lead developer: Sarfez Pharmaceuticals
Modality: Small Molecules

Overview

SF0013 is a preclinical drug candidate currently under development by Sarfez Pharmaceuticals. While specific details regarding its molecular target and mechanism of action have not been publicly disclosed, Sarfez Pharmaceuticals focuses on the development of therapies for heart failure, chronic kidney disease, and uncontrolled hypertension. SF0013 is part of a pipeline that primarily consists of small molecule diuretics and inhibitors targeting renal and cardiovascular pathways. As of early 2024, the candidate remains in the preclinical stage of development.

Beyond the preview

Go deeper on SF0013.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SF0013.

Explore the full profile